Kintegral Advisory LLC Decreases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Kintegral Advisory LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 124,646 shares of the biopharmaceutical company’s stock after selling 5,807 shares during the period. Gilead Sciences makes up about 1.1% of Kintegral Advisory LLC’s holdings, making the stock its 16th biggest holding. Kintegral Advisory LLC’s holdings in Gilead Sciences were worth $11,514,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AMF Tjanstepension AB lifted its position in shares of Gilead Sciences by 14.7% during the third quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock worth $33,645,000 after purchasing an additional 51,390 shares during the last quarter. Swedbank AB lifted its position in shares of Gilead Sciences by 10.2% during the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after purchasing an additional 189,622 shares during the last quarter. Eastern Bank bought a new position in shares of Gilead Sciences during the third quarter worth about $90,000. International Assets Investment Management LLC lifted its position in shares of Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after purchasing an additional 1,622,806 shares during the last quarter. Finally, Cambridge Advisors Inc. bought a new position in shares of Gilead Sciences during the third quarter worth about $222,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 0.1 %

Gilead Sciences stock opened at $109.95 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market cap of $137.03 billion, a price-to-earnings ratio of 297.16, a price-to-earnings-growth ratio of 0.90 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $111.03. The firm’s 50 day moving average price is $95.41 and its two-hundred day moving average price is $88.63.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts predict that Gilead Sciences, Inc. will post 7.94 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.87%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is presently 832.43%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 713,000 shares of company stock worth $67,945,181. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on GILD shares. Barclays increased their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Mizuho increased their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday. Finally, The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.